Haemostatic changes in the pulmonary blood during cardiopulmonary bypass

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 5, 1996, Pages 567-577

  Cardigan, R A ^a   Hamilton Davies, C ^b   McDonald, S ^a   Purdy, G ^a   Mackie, I J ^a   Webb, A R ^b   Machin, S J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiopulmonary bypass; Haemostasis; Leucocyte activation; Pulmonary injury

Indexed keywords

ARTICLE; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; HUMAN; LEUKOCYTE ACTIVATION; LUNG INJURY; PRIORITY JOURNAL;

EID: 0029792102     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199607000-00009     Document Type: Article

References (50)

1. Fowler AA, Hamman RF, Good JT, et al. Adult respiratory distress syndrome: risk with common predispositions. Ann Intern Med 1983; 98: 593-597.
2. Westaby S. Organ dysfunction after cardiopulmonary bypass: a systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 1987; 13: 89-95.
3. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirkiln JW. Complement activation during cardiopulmonary bypass: evidence for the generation of C3a and C5a anaphylotoxins. N Engl J Med 1981; 304: 497-503.
4. Fuher G, Gallimore MJ, Heller W, Hoffmeister H-E. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. Adv Exp Med Biol 1986; 198B: 385-391.
5. Philippou H, Adami A, Boisclair MD, Lane DA. An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass. Br J Haematol 1995; 90: 432-437.
6. Stibbe J, Kluft C, Brommer EJ, Gomes M, De Jong DS, Nayta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375-382.
7. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. Cardiopulmonary bypass induces leucocyte-platelet adhesion. Blood 1992; 79: 1201-1205.
8. Kappelmayer J, Bernabei A, Gikakis N, Edmunds LH, Colman RW. Upregulation of Mac-1 surface expression on neutrophils during simulated extracorporeal circulation. J Lab Clin Med 1993; 121: 118-126.
9. Gordon JL, Pearson JD. Biology of the vascular endothelium. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 303-311.
10. Adachi T, Fukushima T, Usami Y, Hirano K. Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial surface. Biochem J 1993; 269: 523-527.
11. Sjoquist P-O, Marklund S. Endothelium bound extracellular superoxide dismutase type C reduces damage in perfused ischaemic hearts. Cardiovasc Res 1992; 26: 347-350.
12. Westaby S, Fleming J, Royston D. Acute lung injury during cardiopulmonary bypass, the role of neutrophil sequestration and lipid peroxidation. Trans Am Soc Artific Intern Organs 1985; 31: 604-609.
13. Johnson D, Thompson D, Hurst T, et al. Neutrophil mediated acute lung injury after extracorporeal circulation. J Thorac Cardiovasc Surg 1994; 107: 1193-1202.
14. Moat NE, Macnaughton PD, Palleres LCM, Freeman A, Hibbs M, Evans TW. Complement inhibition may attenuate acute lung injury after cardio-pulmonary bypass in pigs. Am Rev Resp Dis 1992; 145: A845.
15. Lu H, Soria C, Commin P-L, et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemostas 1991; 66: 633-637.
16. Videm V, Nilsson L, Venge P, Svevvevig JL. Reduced granulocyte activation with a heparin coated device in an in vitro model of cardiopulmonary bypass. Artificial Organs 1991; 15: 90-95.
17. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in aquired adult heart disease. Circulation 1989; 79: 1.3-1.12.
18. Gallimore MJ, Rees WA, Fuhrer G, Heller W. A direct chromogenic peptide substrate assay for Hageman factor (FXII). Fibrinolysis 1987; 1: 123-128.
19. Gallimore MJ, Friberger P. Simple chromogenic substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein 'like' activity in human plasma. Thromb Res 1982; 25: 293-298.
20. Odegaard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-294.
21. Abildgaard U, Larsen ML. Assay of dermatan sulphate cofactor (heparin cofactor II) activity in human plasma. Thromb Res 1984; 35: 257-266.
22. Sandset PM, Abildgaard U, Petterson M. A sensitive assay of extrinsic pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
23. Seligsohn U, Osterud B, Rapaport S. Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978-988.
24. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
25. Galloway MJ, Mackie MJ, McVerry BA. Elastase-α1-antitrypsin complexes in acute leukaemia. Thromb Res 1985; 38: 311-320.
26. Baugh RJ, Travis J. Human leucocyte granule elastase: rapid isolation and characterisation. Biochemistry 1976; 15: 836-841.
27. Brower MS, Harpel PC. Alpha-1-antitrypsin-human leucocyte elastase complexes in blood: quantification by an enzyme-linked differential antibody immunosorbent assay and comparison with alpha-2-plasmin inhibitor-plasmin complexes. Blood 1983; 61: 842-849.
28. Repo H, Jansson S, Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J Immunol Methods 1993; 164: 193-202.
29. Lowry OH, Rosebrough NJ, Farr L. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-269.
30. Ratliff NB, Young WG, Hackel DB, Mikat E, Wilson MD. Pulmonary injury secondary to extracorporeal circulation. J Thorac Vasc Surg 1973; 65: 425-432.
31. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by new assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemostas 1993; 70: 253-258.
32. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. Adv Exp Med Biol 1986; 198B: 385-391.
33. Wachtfogel YT, Harpel PC, Edmunds LH, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha2-plasmin inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468-471.
34. Unsworth-White J, Leatham E, Cowan D, et al. Heparin causes a marked reduction in FVIIa and the ratio FVIIa: FVIIag during cardiac surgery. Br J Haematol 1994; 86: 67.
35. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
36. Maaoui A, Conard J, Horellou MH, Samama MM. Tissue factor pathway inhibitor (TFPI) during prolonged treatments by unfractionated or low molecular weight heparin. Thromb Haemostas 1993; 69: 681.
37. Anderson T, Halvorsen H, Bajaj SP, Østerud B. Human leucocyte elastase and cathepsin G inactivate factor VII by limited proteolysis. Thromb Haemostas 1993; 70: 414-417.
38. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor Vila by antithrombin III and heparin. J Biol Chem 1993; 268: 767-770.
39. Tanaka K, Wada K, Morimoto T, et al. The role of the protein C-thrombomodulin system in physiologic anticoagulation during cardiopulmonary bypass. Trans Am Soc Artif Intern Organs 1989; 35: 373-375.
40. Journois D, Mauriat P, Pouard P, Marchot P, Amiral J, Safran D. Assessment of coagulation factor activation during cardiopulmonary bypass with a new monoclonal antibody. J Cardiothorac Vasc Anesth 1994; 8: 157-161.
41. Boldt J, Knothe C, Schindler E, Welters A, Dapper FF, Hempelmann G. Thrombomodulin in paediatric cardiac surgery. Ann Thorac Surg 1994; 57: 1584-1589.
42. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995; 90: 244-248.
43. Chabrier PE. The role of endothelin in the vessel wall. Balliere's Clin Haem 1993; 6: 577-591.
44. Uchiba M, Okajima K, Murakami K, Nawa K, Okabe H, Takatsuki K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemostas 1995; 74: 1265-1270.
45. Imai T, Hirata Y, Emori T, Marumo F. Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells. Hypertension 1993; 21: 353-358.
46. Leadley RJ, Humphrey WR, Erickson LA, Shebuski RJ. Inhibition of thrombus formation by endothelin-1 in canine models of arterial thrombosis. Thromb Haemostas 1995; 74: 1583-1590.
47. Donnelly SC, Haslett C. Cellular mechanisms of acute lung injury: implications for future treatment in the adult respiratory distress syndrome. Thorax 1992; 47: 260-263.
48. Hill GE, Alonso A, Thiele GM, Robbins RA. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 1994; 79: 23-27.
49. Gillinov AM, Redmond JM, Zehr KJ, et al. Inhibition of neutrophil adhesion during cardiopulmonary bypass. Ann Thorac Surg 1994; 57: 126-133.
50. Cadroy Y, Gaspin D, Dupouy D, Lormeau JC, Boneu B, Sié P. Heparin reverses the procoagulant properties of stimulated endothelial cells. Thromb Haemostas 1996; 75: 190-195.